Inhibition of AKT2/NF?B/Lipocalin-2 Signaling Axis for the Treatment of Dry Age-related Macular Degeneration (AMD)

Case ID:
Disclosure Date:


       The dry type of age-related macular degeneration (AMD) affects approximately 80-90% of individuals with AMD. Its cause is unknown, it usually progress more slowly than the wet type and at this time, there is no proven medical treatment or cure.  There is one surgical implant that can help some people gain more functional vision. There are also some unproven treatments such as acupuncture, microcurrent stimulation and rheopheresis. Hence, there is great need for therapeutic agents.


Johns Hopkins researchers have identified the specific signaling axis both in an animal model and in human AMD that triggers an inflammatory response in this disease. They have also identified an inhibitor that can be used in this ophthalmic disease. The drug can suppress the inflammatory response in dry AMD patients and thereby lead to cure or delay of the disease progression.


1.Generated unique genetically engineered mice in which lysosome-mediated clearance (both by phagocytosis and autophagy) in RPE cells is compromised, causing the development of features of early AMD.
2.In both the animal models and in human AMD, the AKT2?NF- ?B?LCN-2 signaling axis is involved in activating the inflammatory response, making this pathway a potential target for AMD treatment.
3.Identification of an inhibitor that can delay the progression of the disease phenotype.
 Publication:  J Pathol. 2017 Apr;241(5):583-588.
Patent Information:
For Information, Contact:
Viqar Hussain
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum